Kintor Pharma Starts CDMO Cooperation with CMAB for ALK-1 Cancer Drug

Kintor
Published on: August 22, 2019
Author: Amy Liu

Suzhou Kintor Pharmaceuticals signed a cooperation agreement with CMAB Biopharma (Suzhou), a biologics CDMO, to develop and manufacture Kintor’s ALK-1 mAb. Kintor in-licensed global rights to the candidate from Pfizer, which previously conducted two Phase I trials of the molecule. In the trials, ALK-1 mAb demonstrated a favorable PK and safety profile and reasonable clinical benefits. Kintor says the data suggests the novel antibody, an anti-angiogenesis molecule, has the potential for approval, a first-in-class drug for ALK-1. Source: China Biotoday

Biotechnology Genomics Life Science